Lyell Immunopharma (NASDAQ: LYEL) revenue
Lyell Immunopharma reported revenue of $0.0m for fiscal 2025, 41.0% less than in fiscal 2024 ($0.1m). Since fiscal 2020 its revenue has fallen by 99.5%, an average decline of 65.9% a year.
Lyell Immunopharma's revenue has fallen for 3 years in a row, and its best year of the last 6 was fiscal 2022. The biggest drop was in fiscal 2023, −99.8%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $0.0m | −41.0% | −$269.4m | −748,344.4% |
| 2024 | $0.1m | −53.1% | −$358.8m | −588,123.0% |
| 2023 | $0.1m | −99.8% | −$247.0m | −190,006.2% |
| 2022 | $84.7m | +695.1% | −$187.1m | −220.9% |
| 2021 | $10.7m | +37.3% | −$214.8m | −2,016.7% |
| 2020 | $7.8m | — | −$211.9m | −2,732.6% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Lyell Immunopharma revenue compared with its sector
By revenue for its latest fiscal year, Lyell Immunopharma ranks 402nd of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Lyell Immunopharma, −41.0%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 400th | Avalo Therapeutics | $0.1m | −86.6% |
| 401st | Altimmune | $0.0m | 105.0% |
| 402nd | Lyell Immunopharma | $0.0m | −41.0% |
| 403rd | Amylyx Pharmaceuticals | $0.0m | −100.0% |
| 404th | Artiva Biotherapeutics | $0.0m | −100.0% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Lyell Immunopharma
- How much revenue did Lyell Immunopharma make in fiscal 2025?
- Lyell Immunopharma reported revenue of $0.0m for fiscal 2025, compared with $0.1m in fiscal 2024.
- How much has the revenue of Lyell Immunopharma fallen?
- Between fiscal 2020 and fiscal 2025 it went from $7.8m to $0.0m: 99.5% less, an average decline of 65.9% a year.
- What was the best year for revenue at Lyell Immunopharma?
- Of its last 6 fiscal years, fiscal 2022, with $84.7m.
- Where does Lyell Immunopharma rank in its sector by revenue?
- It ranks 402nd of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Lyell Immunopharma come from?
- From the annual report (Form 10-K) that Lyell Immunopharma files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Lyell Immunopharma files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Lyell Immunopharma: the Lyell Immunopharma page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.